A 42-year-old Chinese woman with chronic hepatitis B and a family history of hepatocellular carcinoma was referred to hepatology clinic.
Full article available to subscribers
Chronic hepatitis B remains an important public health concern in New Zealand, disproportionately affecting New Zealanders from hepatitis B–endemic regions.1 With increased utilisation of liver imaging for hepatocellular carcinoma surveillance, clinicians are increasingly confronted with incidental findings. We describe a case of porta hepatis schwannoma identified on routine liver imaging. Primary hepatobiliary schwannomas are exceedingly rare, with only a small number of cases reported in the literature. Their radiological appearance is often non-specific, frequently mimicking malignant lesions, highlighting the diagnostic and management challenges posed by rare benign lesions detected through surveillance imaging.
A 42-year-old Chinese woman with chronic hepatitis B and a family history of hepatocellular carcinoma was referred to hepatology clinic. She was on antiviral therapy with normal liver enzymes and an undetectable viral load. Alpha-fetoprotein was not elevated and there was no biochemical evidence of advanced liver disease. Transient elastography demonstrated a median liver stiffness of 4.1kPa, consistent with absent-to-minimal fibrosis. She was asymptomatic, with no other comorbidities. Liver ultrasound demonstrated a 4.4cm well-defined heterogeneous mass at the porta hepatis, separate from the liver (Figure 1). The liver had a smooth contour and a few simple cysts. The gallbladder and biliary tree appeared normal. On multiphase computed tomography (CT) the mass showed predominantly central arterial enhancement with a thick enhancing rind in the portal venous phase, without vascular invasion or biliary obstruction (Figure 2).
View Figure 1–2, Table 1.
Endoscopic ultrasound-guided fine-needle aspiration demonstrated S100-positive spindle cells characteristic of schwannoma. Gastrointestinal stromal tumour (GIST), fibroblastic and smooth muscle tumours were argued against with negative staining for cluster of differentiation 117 (CD117), discovered on GIST-1 (DOG1), CD34, smooth muscle actin (SMA) and desmin.2 Following surgical review, the patient underwent open excision of a porta hepatis mass adjacent to the hepatic artery and portal vein. The lesion was dissected free with macroscopically clear margins. Recovery was uncomplicated and the patient was discharged on post-operative day 3. Histology confirmed a schwannoma focally abutting the resection margin without malignancy. CT at 5 months showed expected post-operative stranding at the porta hepatis. Repeat surveillance imaging was planned at 12 months.
In alignment with international goals, the Hepatitis Foundation of New Zealand aims to increase engagement in care among the estimated 94,000 people living with chronic hepatitis B nationally.3 As imaging-based surveillance expands, clinicians may increasingly encounter incidental or indeterminate hepatobiliary lesions. This report describes one such case requiring further imaging, multidisciplinary review, histopathological diagnosis and surgical management.
Schwannomas most commonly arise from the vestibulocochlear nerve as vestibular schwannomas,4 but rarely occur in the extremities, trunk and gastrointestinal5 or respiratory tracts.6 Only several dozen cases of hepatobiliary schwannoma have been reported.5,7 Imaging appearances are variable, often mimicking malignant lesions including hepatocellular carcinoma, cholangiocarcinoma, GIST and metastases, with definitive diagnosis requiring histopathology with immunohistochemistry. In selected cases, adjunctive investigations such as serum tumour markers may suggest an alternative malignant diagnosis.
Surgical resection of benign hepatobiliary schwannoma is associated with favourable outcomes. In the largest identified review of hepatic schwannoma with 30 cases, all patients with benign lesions who underwent resection survived to follow-up completion.5 A review of 15 porta hepatis schwannoma cases reported no recurrence after resection among patients with available follow-up (3–41 months) (Table 1).7
The significance of focal tumour involvement at the resection margin remains uncertain. Evidence from benign spinal and peripheral nerve schwannomas suggests an indolent course despite residual disease.8,9 Malignant hepatobiliary schwannoma5 and malignant transformation of benign schwannoma have been reported,10 though both appear exceptionally rare, leaving no clear consensus on management of positive margins.
This case illustrates how surveillance-detected lesions—even when histologically benign—can present management dilemmas, underscoring the importance of multidisciplinary review and shared decision making in balancing oncological risk, procedural risk and patient tolerance for uncertainty.
Jonathan J Sheu: Gastroenterology Registrar, Department of Gastroenterology and Hepatology, Auckland City Hospital, Auckland.
Judy C Huang: Gastroenterologist, Department of Gastroenterology and Hepatology, Middlemore Hospital, Auckland.
Adam SR Bartlett: Associate Professor of Surgery, Hepatobiliary and Pancreatic (HBP) and General Surgeon, Department of General Surgery, Auckland City Hospital, Auckland.
Ethics: Confirmation was obtained from the Health and Disability Ethics Committees (HDEC) that this project was out of the scope for HDEC review. Written patient consent was obtained.
Jonathan J Sheu: Department of Gastroenterology and Hepatology, Auckland City Hospital, 2 Park Road, Grafton, Auckland 1023, New Zealand.
Nil.
1) Horsfall E, Gane E, Anwar A, et al. Chronic hepatitis B infection-an unmet medical need in New Zealand 35 years after universal neonatal vaccination. N Z Med J. 2020;133(1519):70-80.
2) Miettinen M. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. Histopathology. 2014;64(1):101-118. doi: 10.1111/his.12298.
3) The Hepatitis Foundation of New Zealand. Annual Report July 2023 - June 2024 [Internet]. New Zealand: The Hepatitis Foundation of New Zealand; 2024 [cited 2026 May 28]. Available from: https://www.hepatitisfoundation.org.nz/site_files/36909/upload_files/The%20Hepatitis%20Foundation%20Annual%20Report%2023-24.pdf?dl=1
4) Propp JM, McCarthy BJ, Davis FG, Preston-Martin S. Descriptive epidemiology of vestibular schwannomas. Neuro Oncol. 2006;8:(1)1-11. doi: 10.1215/S1522851704001097.
5) Wan DL, Zhai ZL, Ren KW, et al. Hepatic schwannoma: A case report and an updated 40-year review of the literature yielding 30 cases. Mol Clin Oncol. 2016;4(6):959-964. doi: 10.3892/mco.2016.850.
6) Kadriyan H, Savita Gera NMM, Ajmala IE, et al. Respiratory tract obstruction due to intraluminal tracheal schwannoma. The first report in Indonesia. Crit Care Shock. 2025;28(6):287-294.
7) Yin SY, Zhai ZL, Ren KW, et al. Porta hepatic schwannoma: case report and a 30-year review of the literature yielding 15 cases. World J Surg Oncol. 2016;14:103. doi: 10.1186/s12957-016-0858-9.
8) Fehlings MG, Nater A, Zamorano JJ, et al. Risk Factors for Recurrence of Surgically Treated Conventional Spinal Schwannomas: Analysis of 169 Patients From a Multicenter International Database. Spine (Phila Pa 1976). 2016;41(5):390-398. doi: 10.1097/BRS.0000000000001232.
9) Ten Hove FL, Ciggaar IA, Coerkamp EG, et al. Long-term Follow-up with MRI Scans After Enucleation of Peripheral Nerve Schwannomas: Results From a Single-center Case Series. World Neurosurg. 2024;189:e427-e434. doi: 10.1016/j.wneu.2024.06.081.
10) Ramineni M, Ulici V, Hicks DG, et al. Rapid Malignant Transformation of a Biopsy Proven Sporadic Soft Tissue Schwannoma to Spindle Cell MPNST With TP53 mutation as an Early Event. Int J Surg Pathol. 2025;33(8):1807-1815. doi: 10.1177/10668969251340430.
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz